Chidinma Pamela Ononiwu

Chidinma Pamela Ononiwu

Auto-generated profile, based on publicly available information

Chidinma Pamela Ononiwu

Department of Biochemistry, Faculty of Biological Sciences, University of Nigeria, Nsukka, Nigeria

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Pharmaceutical Biology
Verified
Journal Article
Open access
OEOsmund Chukwuma Enechi
Osmund Chukwuma Enechi
CAChristian Chijioke Amah
Christian Chijioke Amah
IOInnocent Okagu
Innocent Okagu
COChidinma Pamela Ononiwu
Chidinma Pamela Ononiwu
VAVitalis Chukwumalume Azidiegwu
Vitalis Chukwumalume Azidiegwu
ENEmmanuel Elekweuwa Ndukwe
Emmanuel Elekweuwa Ndukwe
Context: The resistance of Plasmodium species to many available antimalarials calls for a continuous search for newer antimalarial agents. One possible source of new antimalarials is from natural sources such as Fagara zanthoxyloides Lam (Rutaceae), a medicinal plant used traditionally for treating malaria in South-Eastern Nigeria, Uganda and Asia. Objectives: To investigate the application of methanol extracts of F. zanthoxyloides in combating malaria infection and its associated disorders. Materials and methods: Methanol extracts of F. zanthoxyloides leaves (MEFZ) were evaluated for in vivo antimalarial activity. MEFZ at doses of 200, 400, and 600 mg/kg/d were administered orally for 4 consecutive days (days 0–4) to P. berghei-infected mice. The possible ameliorative effects of MEFZ on malaria-associated organ malfunctions were also assessed. Results: At 200, 400 and 600 mg/kg b.w., respectively, MEFZ produced 82.37% and 68.39%, 84.84%, and 90.75%, 95.95% and 92.67% chemosuppression and inhibition of P. berghei, respectively, comparable to 98.67% and 97.29% by combisunate, a standard antimalarial. The IC50 of MEFZ was estimated to be 235.23 mg/kg b.w. Similarly, treatment of parasitized mice with MEFZ significantly restored the malaria-modified haematological and biochemical status of the parasitized-MEFZ-treated mice compared with parasitized-untreated mice. MEFZ was tolerable up to 5000 mg/kg b.w dose; hence, the LD50 is above 5000 mg/kg b.w. Discussion and conclusions: The results of this curative assay demonstrated that MEFZ has antimalarial effects and normalized haematological and biochemical aberrations generated by malaria. The isolation of the antimalarial principles in MEFZ is warranted; they could be lead molecules for the development of new antimalarials.

11 October 2021 in Clinical Phytoscience
Verified
Journal Article
Open access
PDF file
OEOsmond Chukwuma Enechi
Osmond Chukwuma Enechi
CAChristian Chijioke Amah
Christian Chijioke Amah
IOInnocent Okagu
Innocent Okagu
POPamela Chidinma Ononiwu
Pamela Chidinma Ononiwu
ANAlice Chinwendu Nweke
Alice Chinwendu Nweke
BCBlessing Chiamaka Chukwurah
Blessing Chiamaka Chukwurah
Background: Malaria has continued to be a threat to man and his wellbeing, especially Africans and Asians. New antimalarial drugs are urgently needed to mitigate malaria treatment failure due to resistant Plasmodium species. Medicinal plants used by indigenous Nigerians for treating fever and malaria such as Sida acuta Burm.f. (Malvaceae) could be a promising source of lead compounds for developing new generations of antimalarial drugs. The effects of ethanol extract of S. acuta leaves (EESAL) on malaria parasitemia, haematological and biochemical status of P. berghei-infected mice were investigated, using the 4-day curative test. Methodology: EESAL was prepared by maceration method. The phyto-constituents and acute toxicity profile of the extract were evaluated using standard protocols. In addition, malaria parasitemia and chemo-suppression, and indicators of haematological and biochemical status of P. berghei-infected mice treated with EESAL were assessed. Results: At 200, 400 and 600 mg/kg/d b.w., p.o doses for 4 consecutive days, EESAL significantly (p < 0.05) decreased parasitaemia and suppressed malaria parasite by 89.64%, 95.95% and 97.38%, respectively comparable to negative control. The reduction in percentage malaria parasitemia by EESAL is comparable to Artemether (140 mg/kg/d b.w., p.o) used as standard antimalarial drug in this study. The packed cell volume (PCV), haemoglobin (Hb) concentration, and red blood cell (RBC) and white blood cell (WBC) counts of negative control are significantly (p < 0.05) higher than normal control. However, parasitized-EESAL-treated mice have significantly (p < 0.05) higher PCV value, Hb concentration and RBC and WBC counts than negative control. Similarly, treatment of parasitized mice with EESAL restored some indicators of the antioxidant, lipid peroxidation, lipid profile and liver status altered by malaria. In addition, EESAL was tolerable up to 5000 mg/kg b.w., p.o. Conclusion: These results indicate that the EESAL possesses antimalarial activity and normalizes alterations in haematological and biochemical status of malaria-infected mice.

22 June 2022 in International Journal of Diabetes in Developing Countries
Verified
Journal Article
Closed access
PDF file
PJParker Joshua
Parker Joshua
CEChinelo Grace Enwelu
Chinelo Grace Enwelu
BOBonaventure Chukwunonso Obi
Bonaventure Chukwunonso Obi
RARita Asomadu
Rita Asomadu
COChidinma Pamela Ononiwu
Chidinma Pamela Ononiwu
EAEdwin Olisah Alumanah
Edwin Olisah Alumanah

18 November 2024 in Laboratory Animal Research
Verified
Journal Article
Open access
PDF file
COChidinma Pamela Ononiwu
Chidinma Pamela Ononiwu
PJParker Joshua
Parker Joshua
CAChristian Chijioke Amah
Christian Chijioke Amah
RARita Asomadu
Rita Asomadu
EOEkezie Matthew Okorigwe
Ekezie Matthew Okorigwe
OAOnyinyechi Becky Adiele
Onyinyechi Becky Adiele
Background: Myocardial Infarction still persists as the most prevalent cardiovascular disease and is a top cause of morbidity and mortality in doxorubicin treated cancer patients. This study evaluated the prophylactic effect of the ethanol root bark extract of Cleistopholis patens (ERBECP) against doxorubicin-induced myocardial infarction in wistar rats. Extraction, preliminary phytochemical analysis, acute toxicity study and body weight (b.w.) of ERBECP were achieved using standard methods. Phyto-constituents in ERBECP were indentified using Gas Chromatography-Mass Spectrometry (GC–MS) technique. Thirty (30) male albino Wistar rats of average b.w. ranging between 100 and 130 g were divided into six groups of five rats each. Groups I, II and III served as normal, doxorubicin (DOX) and standard (Vasoprin 150 mg/kg b.w) controls respectively, while groups IV, V and VI were orally pre-treated with the extract (200, 400 and 600 mg/kgb.w) for two weeks prior to intraperitoneal induction of cardiotoxicity with DOX (20 mg/kg bw) on day 14. Results: Disturbances in serum cardiac function bio-markers such as; Cardiac Troponin-I (CTnI), Creatine Kinase (CK), Lactate Dehydrogenase (LDH), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT). Lipid profile markers such as; Total cholesterol (TC), Triacylglycerol (TAG), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL). Oxidative stress markers such as; Malondialdehyde (MDA), Superoxide Dismutase (SOD), Catalase (CAT), Glutathione (GSH) confirmed the induction of myocardial infarction. Histological assessment of heart tissues was performed to validate biochemical results. The GC–MS analysis of ERBECP identified a total of 69 compounds. Safety profile of the aqueous extract was safe for the animals up to the highest dose of 5000 mg/kg b.w. Pre-treatment of DOX group with ERBECP could significantly increase the b.w. compared to the DOX-treated group during the experimental period of 2 weeks. There were significant (p < 0.05) alterations in the levels of CTnI, CK, LDH, AST, ALT and lipid profile indices in the DOX control rats. Also, significant (p < 0.05) increase was observed in MDA and decrease in SOD, CAT and GSH in the DOX control rats. However, administration of the extract significantly (p < 0.05) normalized these alterations and reversed the architectural changes in the heart. The 69 compounds were screened against the target protein (CBR1); we identified seven hits based on the docking score and interactions with the active site residues. All the C. patens constituents had MW (g/mol) less than 500, HBA < 10 and HBD not more than 5. Apart, 9-Octadecenoic acid (Z)-, 2,3-dihydroxy propyl ester and Estra-1,3,5(10)-trien-17. beta. -ol, all the constituents had LD50 lower than 2000 mg/kg. Conclusions: The findings reveals ERBECP demonstrated promising potential and can be exploited in the development novel cardiac therapeutic agents.

27 July 2022 in International Journal of Diabetes in Developing Countries
Verified
Journal Article
Open access
PDF file
PJParker Joshua
Parker Joshua
CEChinelo Grace Enwelu
Chinelo Grace Enwelu
BOBonaventure Chinonso Obi
Bonaventure Chinonso Obi
RARita Asomadu
Rita Asomadu
COChidinma Pamela Ononiwu
Chidinma Pamela Ononiwu
EAEdwin Olisah Alumanah
Edwin Olisah Alumanah